Atlas Trials

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Clinical trial NCT01649297 · COMPLETED

Trial details

NCT number
NCT01649297
Sponsor
Boehringer Ingelheim
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Diabetes Mellitus, Type 2
Start date
2012-10-01
Primary completion
2013-12-01
Enrollment
983

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.